Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery

Iti Chauhan1*, Mohd Yasir2, Madhu Verma1, Alok Pratap Singh1

1Department of Pharmaceutics, I.T.S College of Pharmacy, Muradnagar, Ghaziabad- 201206, Uttar Pradesh, India.
2Department of Pharmacy, College of Health Science, Arsii University, Asella, Oromia Region, Ethiopia.

Abstract
Nanostructured lipid carriers (NLCs) are novel pharmaceutical formulations which are composed of physiological and biocompatible lipids, surfactants and co-surfactants. Over time, as a second generation lipid nanocarrier NLC has emerged as an alternative to first generation nanoparticles. This review article highlights the structure, composition, various formulation methodologies, and characterization of NLCs which are prerequisites in formulating a stable drug delivery system. NLCs hold an eminent potential in pharmaceuticals and cosmetics market because of extensive beneficial effects like skin hydration, occlusion, enhanced bioavailability, and skin targeting. This article aims to evoke an interest in the current state of art NLC by discussing their promising assistance in topical drug delivery system. The key attributes of NLC that make them a promising drug delivery system are ease of preparation, biocompatibility, the feasibility of scale up, non-toxicity, improved drug loading, and stability.

Introduction
Currently, the field of nanotechnology is intensely exploited for drug delivery technology for passive and active targeting via various routes of administration. The application of nanotechnology in transdermal and topical drug delivery has proclaimed a new domain in the delivery of pharmaceuticals via the skin. Nanoparticles are defined as colloidal particulate systems having dimensions between 10-1000 nm.1 Solid lipid nanoparticles (SLNs) were conceptualized in early 1990s by Professor R.H. Müller (Germany) and Professor M. Gasco (Italy) as a novel formulation possessing several advantages e.g. the use of biocompatible lipids, least use of organic solvents during formulation, high in vivo stability and broad application spectrum.2 SLNs are colloidal particles prepared from solid lipids (solid at room temperature and body temperature), surfactants, active ingredient and water. Still, SLNs experience certain limitations like poor drug loading capacity, unpredictable gelation tendency, polymorphic transitions and drug leakage during storage.1,3 Nanostructured lipid carriers (NLCs) spring up as second generation of lipid nanoparticles to overcome the shortcomings of first generation i.e. SLNs. Biodegradable and compatible lipids (solid and liquid) and emulsifiers are used for the preparation of NLCs. Liquid lipids (oil) incorporation causes structural imperfections of solid lipids leading to a less ordered crystalline arrangement which avert drug leakage and furnish a high drug load.2,4 In last few years, NLCs have gained attention of researchers as an alternative of SLNs, polymeric nanoparticles, emulsions, microparticles, liposomes etc.5 These nanocarriers possess the utility in delivery of hydrophilic as well as lipophilic drugs. NLCs have emerged as a promising carrier system for the delivery of pharmaceuticals via oral, parenteral, ocular, pulmonary, topical, and transdermal route. Recently, NLCs are also being exploited in brain targeting, chemotherapy, gene therapy, food industry and delivery of cosmeceuticals and nutraceuticals.5 Table 1 mentions the advantages and disadvantages of NLC.

Types of NLC
Depending on the location of incorporated drug moieties in NLC, following three types of morphological models (Figure 1) has been proposed:

NLC type I (imperfect crystal model)
Imperfect crystal type NLC consists of a highly disordered matrix with many voids and spaces which can accommodate more drug molecules in amorphous clusters. These imperfections in the crystal order are acquired by mixing solid lipids with adequate amount of liquid lipids (oils). Due to varying chain length of fatty acids and the mixture of mono-, di-, and triacylglycerols, the matrix of NLC is not able to form a highly ordered structure. Mixing spatially different lipids increases drug

*Corresponding Author: Iti Chauhan, Tel: 91-860988988, Fax: (01232) 225380, Email: itichauhan@its.edu.in
© 2020 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
payload capacity however this model offers minimum entrapment efficiency.\(^8\)\(^9\)

**NLC type II (multiple type)**

Multiple type NLC is oil/lipid/water type. Lipophilic drugs are more soluble in liquid lipids than solid lipids. This idea leads to the development of multiple type NLC using high liquid lipid content. Oil moieties, at low concentrations, are effectively dispersed in the lipid matrix. The addition of oil beyond its solubility induces phase separation forming small nano compartments of oil encircled in the solid matrix. Type II model offer advantages like high drug entrapment efficiency, controlled drug release and minimized drug leakage.\(^9\)\(^10\)

**NLC type III (amorphous model)**

Amorphous type NLC is formulated by carefully mixing lipids in such a way as to minimize the drug leakage due to process of crystallization. Specific lipids such as hydroxyl octacosanyl, hydroxyl stearate, isopropyl myristate or dibutyl adipate form solid yet non-crystalline particles. The lipid matrix exists in a homogenous amorphous state.\(^8\)\(^10\)

**Excipients used in formulating NLC**

Generally, NLCs are composed of lipid (s) (solid as well as liquid), surfactant(s), organic solvent and other agents like counter-ions and surface modifiers. Table 2 enlists some of the excipients used for formulating NLC.

**Lipids**

The primary component of nanostructure lipid carriers that govern drug loading capacity, prolong action and stability of the formulations is lipid. Solid lipids like fatty acids, triglyceride, diglyceride, monoglyceride, steroids and waxes have been used for formulating NLC.\(^11\)

Physiologically acceptable, biodegradable, non-toxic and generally-recognized-as-safe (GRAS) status lipids are preferred for preparation of lipid nanoparticles.\(^10\)

Choice of suitable lipids is essential preceding their utilization in preparation of nanoparticulate carriers. The type and structure of lipid affects various characteristics of nanocarriers. Practically, solubility or evident partition coefficient of bioactives in the lipid has been suggested as the best fitting criteria for choosing a suitable lipid. The solubility of the drug molecules in lipid is interpretative as it affects drug loading and encapsulation efficiency.\(^10\)
Degree of crystallization of various lipids employed also affect drug entrapment and loading, size and charge, and efficacy.\(^\text{12}\)

On account of higher viscosity of dispersed phase, because of higher melting lipids, the average particle size of nano dispersion increases. Shape of lipid crystals, lipid hydrophilicity, variation in composition are additional lipid related parameters that may influence quality of NLC. It has been found that a 5- 10% hike in lipid amount leads to larger particle size.\(^\text{13}\)

### Surfactants

The type and concentrations of surfactant exert influence on quality and efficacy of NLC. It has been found that toxicity, physical stability and crystallinity of NLC are greatly influenced by choice of surfactant.\(^\text{14}\) Surfactant systems also have an impact on extent of drug dissolution and drug permeability. Surfactants are chosen based on of route of administration, hydrophilic-lipophilic balance (HLB) value, effect on particle size and lipid modification. Surface active agents (emulsifiers) are adsorbed on the interface where they reduce the tension between lipid and aqueous phases because of their amphipathic nature.\(^\text{5}\)

During the formulation of NLC, crystallization of colloid particles goes along with solidification, but the surface area of particle increase remarkably during crystallization so that the whole system become unstable. Hence, surfactant is a requisite to improve interface quality of nanoparticles to attain stability.\(^\text{15}\) Modifying the surfactant system compositions may govern the miscibility of chemical components in NLCs, and hence the stability.\(^\text{14}\)

Required HLB (rHLB) plays an important role while selecting suitable type and amount of surfactant for NLC formulation.\(^\text{16}\) rHLB of lipids and lipid matrix is determined to calculate the amount of emulsifiers to be added in formulation. The rHLB value for lipid is the HLB value of emulsifier which is necessary for appropriate emulsification i.e. reduction of interfacial tension between oil and water phase. This also assists in achieving a stable nano system and small particle size of NLCs.\(^\text{17,18}\)

By determining rHLB a right combination of emulsifiers with least concentration can be employed for formulation. rHLB for lipids (solid and liquid) and lipid matrix is calculated experimentally by dispersing in blends of surfactant with different HLB values. The mixture is put through high pressure homogenization and analyzed for least particle size.\(^\text{16,18,19}\)

### Other ingredients

Organic salts and ionic polymers may be employed as counter-ions in formulation of nano structure carriers to overcome the challenge of encapsulating water soluble drug molecules. Surface-modifiers are another category of excipients used in formulation of NLC to minimize their phagocytic uptake by the macrophages in reticuloendothelial system (RES). Lipid particles are coated with hydrophilic polymers like PEG, poloxamines or poloxamers to increase the residence time of drug molecules in systemic circulation. Surface modification may offer other advantages like enhanced physical stability and biocompatibility, drug targeting, increased transport across epithelium.\(^\text{10,20}\)

### Methods of preparing NLC

#### High-pressure homogenization technique

This technique is powerful and reliable for the commercial-scale production of NLCs. High pressure used in homogenization technique makes it possible to avoid use of organic solvents in preparations and render them eco friendly. Additionally high-pressure homogenization is easy to scale up and an attractive technique being used in the manufacturing of pharmaceuticals and cosmetics for topical application.\(^\text{21}\) Hot homogenisation is performed at elevated temperature and cold homogenization is done below room temperature. Active ingredient is dissolved or dispersed in the molten lipid before to the high pressure homogenization, in both approaches. High pressure (100–2000 bar) moves the fluid in the narrow gap in homogenizer.

#### Hot homogenization

In this approach homogenization is conducted at elevated temperature. The solid lipids are melted at a temperature above 5-10°C above their melting point. A dispersion is obtained by adding liquid lipid and drug to be encapsulated. The mixture is dispersed in aqueous

---

**Table 2. Excipients used in formulating NLCs\(^\text{6,7,11}\)**

| Ingredient            | Examples                                                                 |
|-----------------------|---------------------------------------------------------------------------|
| Solid lipid           | Bees wax, Caranauba wax 2442, Stearic acid, Cetyl Palmitate, Apifil®, Cutina CP®, Dynasan® 116, Dynasan®118, Precirol ATO, Compritol®888 ATO, Eliocons® C 26, Immigrator 9000®, Precirol® ATO 5, tristearin, cholesterol, Palmitic acid |
| Liquid lipids (oils)  | Cetyl alcohol, Miglyol® 812, Castor oil, oleic acid, Davana oil, Palm oil, Olive oil, Isodecyl oleate, Paraffin oil, propylene glycol, dicaprylocaprate, linoleic acid, decanoic acid, Argan oil, coconut oil |
| Emulsifying agents    | Pluronic® F68 (poloxamer 188), Pluronic® F127 (poloxamer 407), Tween 20, Tween 40, Tween 80, polyvinyl alcohol, Soluctol® HS15, trehalose, sodium deoxycholate, Sodium glycocholate, sodium oleate, polyglycerol methyl glucose distearate, Tego®Care 450, Tween®60, Maquat® SC 18Maquat® BTMC-85%, Egg lecithin, soya lecithin, phosphatidyicholines, phosphatidylethanolamines, Gelucire® 50/13, Miranol ultra 32 |
| Counter-ions          | Sodium hexadecyl phosphate, Monodecyl phosphate, Mono hexadecyl phosphate, Mono octyl phosphate, Dextran sulphate sodium salt, Hydrolysed and polymerised epoxidised soybean oil |
solution of surfactant (s) heated to same temperature by high shear mixing device and leads to formation of pre-emulsion. The pre-emulsion is introduced in high pressure homogenizer at controlled temperature. Generally 3 to 5 cycles at 500-1500 bar are sufficient for homogenization. The lipid recrystallizes and causes formation of nanoparticles as nanoemulsion is gradually cooled down. Employment of high temperature during the process may lead to degradation of heat sensitive ingredients. Another problem which may arise is reduction in emulsifying capacity of surfactants due to high temperature as surfactants have cloud point lower than 85°C. This may induce instability to nanocarriers.4,21-23

**Cold homogenisation**

In this technique lipid melt containing active agent is rapidly cooled to being solidify using liquid nitrogen or dry ice, then milled and ground before being dispersed in cold surfactant phase and subsequently homogenized at room temperature. Pressure used in cold process is higher i.e. 5-10 cycles of 1500 bar. This approach minimizes the thermal exposure of drug and well suited for thermolabile drugs. Improved drug entrapment efficiency and uniform distribution of drug within the lipid are other benefits of the method. However it results in nanoparticles of more variable sizes.4,22-24

**Solvent-emulsification evaporation method**

In this method, the lipids (solid lipid + liquid lipid) along with drug are dissolved in a water immiscible organic solvent (cyclohexane, chloroform).25 The obtained mixture is dispersed into aqueous solution of emulsifiers producing an o/w emulsion. Evaporation under reduced pressure is employed to remove solvent from the emulsion. Evaporation leads to the dispersion of nanoparticles in the aqueous phase (by lipid precipitation in the aqueous medium). This method avoids any thermal stress, but usage of organic solvent is a disadvantage. Particle size can vary from 30-100 nm according to the solid lipid and surfactant.6,24

**Solvent-emulsification diffusion method**

In this technique, solvent and water are mutually saturated to maintain initial thermodynamic equilibrium.

Afterwards, the lipids and drug is dissolved in the water-saturated solvent. Solvent containing drug and lipids are emulsified in a solvent-saturated aqueous emulsifier solution by a homogenizer to form an o/w emulsion. The lipid nanoparticles precipitate after dilution with excess water (ratio: 1:5–1:10) due to diffusion of the organic solvent from the emulsion droplets to the continuous phase. The solvent can be removed by ultrafiltration or lyophilisation. Solvent diffusion is more innovative and most of the solvent employed show a better safety profile compared to volatile solvents.25

**Microemulsion method**

In this approach, the solid lipid is melted, followed by addition of liquid lipid and solubilization of drug in the subsequent mixture. Separately, a mixture of emulsifier, co-emulsifier and water is heated at same temperature. Both the lipid and the aqueous phase are mixed in appropriate ratios and gently stirred to produce thermodynamically stable oil in water hot microemulsion. The hot microemulsion is quickly dispersed into an excess of chilled water (0-4°C) with vigorous stirring. The dilution causes the breakdown of microemulsion into a nanoemulsion with ultrafine particles. The ratio of the hot microemulsion to cold water usually lies in the range of 1:10 to 1:50. As the microemulsion is diluted by cold water, the internal lipid droplets recrystallize to form nanosize carriers. The size of the nanoparticles depends on the droplet size of microemulsion and temperature difference between microemulsion and ice water. Rapid cooling and hence solidification can prevent the aggregation of particles and lead to production of smaller particles.26 NLC dispersions formed by this method contained large quantity of particles in the micron range; therefore, in this condition, the time of stirring, percentage of lipids, and amount of drug were optimized in order to obtain the appropriate size and higher entrapment efficiency. The method does not require any special equipment or energy for production of NLC; hence it is simple to commercially scale up the technique.22,27,28

**Double emulsion technique**

This method is mainly used for the production of lipid nanoparticles loaded with hydrophilic drugs. This technique overcomes the problem of escapism of water soluble moeity in aqueous phase from oily phase as investigated in microemulsion method.29 In this method, drug is firstly dissolved in aqueous solvent (inner aqueous phase) and then is dispersed in lipid phase (Molten solid lipid + liquid lipid+ lipophilic surfactant+ lipophilic active moiety) to produce primary emulsion (w/o). Both lipid and the aqueous phase are maintained at same temperature. Stabilizer prevents loss of drug to the external phase during solvent evaporation. Afterwards, primary emulsion is dispersed into a large volume of surfactant aqueous solution followed by sonication to form a double emulsion (w/o/w). The lipid nanoparticles are then purified by ultrafiltration or solvent evaporation.24,30

**Solvent Injection technique**

It is a viable new technique to manufacture lipid nanoparticles. In this technique, lipids are solubilized in water-miscible solvent (e.g., acetone, methanol, ethanol, isopropyl alcohol) or water-soluble solvent mixture and then rapidly injected into aqueous surfactant solution under continuous stirring. Resultant dispersion is filtered in order to eliminate excess lipid.31 The technique relies on rapid diffusion of the solvent over the solvent-
lipid interfaced with the aqueous phase. The particle size of nanocarriers depends on diffusion rate of the organic solvent through the lipid-solvent interface. This method offers the advantage of easy handling, efficiency, versatility, no employment of technical equipment (e.g., high-pressure homogenizer) and use of approved organic solvents.

**High shear homogenization and ultrasonication**
One of the methods for the production of NLCs is high shear homogenization or ultrasonification. These dispersing techniques employ devices to prepare nanocarriers. Solid and liquid lipid is melted and dispersed in an aqueous surfactant solution under high shear homogenization or ultrasonication resulting in formation of nanodispersion. Intense shear forces necessary for the nano-emulsification are generated by ultrasonic cavitation which produces violently and asymmetrically imploding vacuum bubbles and break up particles down to the nanometer scale.

Probe-type ultrasonication produce desired effects like homogenization, dispersion, deagglomeration, milling and emulsification. The type and concentration of lipid and surfactant, their ratio, time of sonication or agitation, speed are some of the parameters to be optimized to obtain a reproducible method resulting small size nanocarriers. Low dispersion quality is a disadvantage of high shear homogenization and ultrasonication. Dispersion quality of the lipid nanoparticles produced by these techniques is often affected by the presence of microparticles leading to physical instability upon storage. Metal contaminations from the equipment is the other important problem associated with ultrasonication.

**Phase inversion technique**
It is a novel, cost effective and solvent-free approach for the formulation of lipid nanocarriers that involves the phase inversion from o/w to w/o emulsion. It involve two steps.

Step 1 involves mixing of all the ingredients (lipid, surfactant and water) in optimized proportions. The mixture is stirred and temperature is increased at a rate of 4°C to reach up to 85°C from room temperature. Three temperature cycles (85–60–85-60-85°C) are applied to the system to reach phase inversion zone.

Step 2 results an irreversible shock introduced to break the system, due to dilution with cold water (0°C). This fast addition of cold water causes formation of nanocapsules. Application of a slow magnetic stirring for 5 minutes avoids particle aggregation. Low energy involvement enables the formation of stable transparent dispersions (smaller than 25 nm), which can be used for encapsulation of numerous bioactive compounds.

**Microfluidization method**
The technique involves use of a new, patented mixing technology employing high shear fluid device known as microfluidizer. In this process, the liquid is forced at speed up to 400 m/s through microchannels to an impingement area at high operating pressures. Cavitation and the accompanying shear and impact are accountable for the efficient particle size reduction within the “interaction chamber”. The technique can be utilized on laboratory as well as production scale.

**Membrane contactor technique**
Membrane contactor is used to identify membrane systems that are employed to “Keep in contact” two phases. The lipid phase, at a temperature above its melting point is placed in a pressurized vessel. It is allowed to permeate through ceramic membrane pores under applied pressure to form small droplets. The aqueous phase, under continuous stirring, flow tangentially inside the membrane module, and brush away the droplets formed at the pore outlets. Cooling of the preparation to room temperature leads to the formation of lipid particles. Temperature of aqueous and lipid phase, aqueous phase tangential-flow velocity and pressure of lipid phase and membrane pore size are the process parameters affecting size of lipid nanocarriers. The benefits of this new process of membrane emulsification are commercial scalability and control on particle size by fitting optimized parameters.

**Characterization of NLC**
Appropriate techniques are required for characterizing physicochemical properties of NLC in order to ensure their performance, product quality and stability. Various evaluation parameters like particle morphology, interfacial properties, drug entrapment efficiency, crystallinity studies etc enlighten the workability of NLCs as drug delivery system.

**Particle size measurement**
Particle size of NLC is generally determined by photon correlation spectroscopy (PCS) using Zetasizer which works on Mie theory. Photon correlation spectroscopy (alias dynamic light scattering or quasi-elastic light scattering) is based on the measurement of the fluctuations in scattered light arising from Brownian motion. It provides the average particle size (z-average) and polydispersity of the system as a measure of the particle size distribution. It characterizes particles of few nanometers to about 3 microns. Laser diffractometer (LD) can characterize a wide range from the nanometer to the micrometer range particles. This evaluation is based on the diffraction pattern depicting particle shape and size (explained by Fraunhofer theory). In progression, combining Laser diffraction with Polarization intensity differential scattering technology results in the sizing of particles as small as 10 nm.

Data obtained is interpreted by calculating the volume...
Nanostructure lipid carriers

The technique does not utilize beams caused by these moving particles is measured Doppler anemometry, also known as Laser Doppler velocimetry. The velocity is measured utilizing the technique of Laser Doppler electrophoresis, also known as Laser Doppler velocimetry. The frequency shift of an incident laser beam caused by these moving particles is measured as particle mobility, and this is converted to the zeta potential according to the Henry equation. Zeta potential is influenced by factors like electrical conductivity, pH, and the nature of the reagents.

\[ \text{Zeta potential} = \frac{D_{v(90)} - D_{v(10)}}{D_{v(50)}} \]

Another technique for particle size classification is by field flow fractionation (FFF) based on the size dependent migration and accumulation profile of particles on application of a perpendicular external field in a laminar flow. The classification into different size fractions can be realized by gravitation (sedimentation FFF), by thermophoresis in temperature gradients (thermal FFF), by electric fields (electrical FFF) or by hydrodynamic fields (cross flow FFF).

**Zeta potential**

Zeta potential (ZP) is a key factor for evaluation of the stability of nano dispersion. The ZP determination is based on particle electrophoretic mobility in aqueous medium. Zeta Potential characterizes the surface charge and gives information about long term stability. At higher ZP the particle aggregation is less likely due to electric repulsion while dispersions with lower values tend to coagulate or flocculate, possibly leading to less stability.

Generally the zeta potential of dispersion should be either less than -30 mV or greater than +30 mV for electrostatic stabilization of NLC. Zeta potential estimation can be done by Laser Doppler electrophoresis, using a Malvern ZetaSizer Nano ZS. By applying an electric field across the sample, particles with a zeta potential will migrate toward the electrode of opposite charge with a velocity relative to the magnitude of the zeta potential. The velocity is measured utilizing the technique of Laser Doppler anemometry, also known as Laser Doppler velocimetry. The frequency shift of an incident laser beam caused by these moving particles is measured as particle mobility, and this is converted to the zeta potential according to the Henry equation. Zeta potential is influenced by factors like electrical conductivity, pH, and the nature of the reagents.

**Entrapment efficiency**

It is the influence on the release characteristics that determines the amount of drug loaded in NLC, a prime importance. Entrapment efficiency (Ee) defines the ratio between the weight of entrapped drug and the total weight of drug added to the dispersion. The amount of drug encapsulated per unit weight of the NLC is determined by ultrafiltration-centrifugation method. A known dispersion of NLCs is prepared and centrifugation is performed in a centrifuge tube mounted with an ultralifter. After appropriate dilution the amount of free drug in

**NLC morphology**

Surface morphology of NLC can be observed by transmission and scanning electron microscopy (TEM, SEM), atomic force microscopy (AFM) and PCS. These techniques are tried and true for dimensional and structural characterization of NLCs. Negative staining, freeze-fracture and vitrification by plunge freezing are different methods of sample preparation for TEM which can furnish different information about the colloidal particles. The sample is put on a gold or copper grid with defined mesh size grid and stained with heavy metal salt solution which provides high contrast in the electron microscope. After drying, the sample is viewed in the electron microscope where the Nanoparticles appear bright against the darker background of the stain. Dehydration during sample preparation may lead to structural changes, thus original morphology of nano carriers may get altered. Cryo-transmission electron microscopy (cryo-TEM) and cryo-electron tomography (cryo-ET) is robust and indispensable tool to visualize colloidal drug delivery system. The methodology allows investigation of the sample in a vitrified frozen hydrated state, allowing visualization of nanoparticles basically as they exist in solution. Sometimes use of surfactant in SEM imaging leads to artifacts due to formation of smooth camouflageing coating on particle surface. AFM is a relatively simple and non-invasive technique that could be abused as a main imaging tool to measure & manipulate morphology and size of lipid nanoparticles. AFM offers an upper edge in characterizing heterogeneous materials and providing high grade data. Samples for AFM requires fixation by removal of water, which may cause alteration in the status of emulsifier and polymorphic changes in lipids. The technique does not utilize beams or radiations however a sharp-tipped scanning probe fixed to the free end of a spring like cantilever. Deflection, oscillation or shift in resonance frequency of cantilever motion are used to quantify interaction between the tip and surface of the specimen.
supernatant is determined by spectrophotometer. The entrapment efficiency in the NLCs is calculated by the following equation:

\[
\text{Entrapment Efficiency (\%) = \frac{\text{Wa} - \text{Ws}}{\text{Wa}} \times 100 \%
\]

where, Wa is the initial weight of drug used and Ws is the amount of drug determined in supernatant after separation of the lipid and aqueous phase.

Loading capacity \( Lc \) expresses the ratio between the entrapped drug and the total weight of the lipids. It is determined as follows:

\[
Lc = \frac{\text{Wa} - \text{Ws}}{\text{Wa} - \text{Ws} + \text{Wl}} \times 100 \%
\]

where \( Wl \) is the weight of lipid added in the formulation.

Liquid lipids create a disordered crystal matrix and consequently more space is available for loading large amount of drug, hence enhancing entrapment efficiency. \( Ee \) and \( Lc \) are dependent on several parameters, such as the lipophilic properties of the active pharmaceutical ingredient, the screening of the most appropriate lipid composition/ratio (solid/liquid lipids) and surfactant combination, as well as the production procedure used.

**Crystallinity and polymorphism**

The characterization of the crystallinity of the NLC components is important as the lipid matrix as well as the loaded drug may undergo a polymorphic transitional change leading to a possible undesirable drug leakage during storage. The status of crystallinity of a particle also influences the encapsulation efficiency & release rates. An increment in thermodynamic stability and lipid packing density, while a decrease in drug incorporation rate is observed in the following order: Supercooled melt > alpha modification > beta' modification > beta modification

To investigate crystallinity and polymorphic status, differential scanning calorimetry (DSC) and X-ray diffraction (XRD) experiments are performed. DSC gives the heat lost or gained because of physical or chemical changes within a sample as a function of the temperature. DSC measurements reveal the status of lipid, melting and crystallization behavior of solid lipids in nanostructures. DSC analysis is carried out on pure drug, pure lipids and nanoparticles. DSC characterization can illuminate NLC structure through the mixing behavior of solid lipids with liquid lipids. The breakdown and fusion of the crystal lattice by heating or cooling the sample furnish exclusive information of polymorphism, crystal ordering, eutectic mixtures, glass transition processes and drug lipid interactions. Recrystallization index (RI) is a parameter to perform comparative study of the crystallinity between the developed formulations. It can be calculated from the following formula:

\[
RI = \frac{\Delta H_{NLC}}{\Delta H_{bulk}} \times \text{Concentration of lipid} \times 100
\]

where \( \Delta H_{NLC} = \) Melting enthalpy of 1 g NLC suspension, \( \Delta H_{bulk} = \) Melting enthalpy of 1 g bulk lipid, \( \Delta H \) is given in J/g and the concentration is given by the percentage of lipid phase.

Gonullu et al determined Crystallization index (CI %) to determine the crystalline state of the drug in formulations.

\[
CI = \frac{Ms}{Mp} \times 100
\]

where, \( Ms = \) Melting enthalpy (J g–1) of lipid nanoparticles, \( Mp = \) Melting enthalpy (J g–1) of pure solid lipid, and \( Y \) represents solid lipid concentration (%) in nanoparticle dispersion.

An increase in amount of liquid lipid lowers the crystallinity and increases the defects in highly ordered structure of NLCs. The principle behind performing DSC rests on different enthalpy and melting point for different lipid changes. NLCs having a smaller size, therefore a higher surface area and employing more surfactants showed a decline in enthalpy and melting point of lipids.

**Surface tension measurement**

An increase in concentration of emulsifier lowers the interfacial tension of system due to the emulsification process. Surface tension of the lipid nanoparticles is often measured by the Wilhelmy plate method. The measurement of the contact angle is another method for detecting surface tension of the nanoparticulate systems.

Kibron instrument is a high precision, easy to use torsion balance instrument to measure surface tension of NLC. It employs the combination of maximum pull force technique and a unique ultrasensitive microbalance with Kibron’s proprietary sensor. The instrument is at par in the technique of determining surface tension in comparison to platinum Wilhelmy plates or Du Noüy ring.

**Evaluation of additional colloidal structures**

In various cases, it has been observed that other colloidal structures like micelles, mixed micelles, liposomes,
supercooled melts, accompany lipid nanoparticles. Evaluating these colloidal structures is quite a difficult task due to their size similarity, low resolution of PCS to image multimodal size distribution. Sample preparation may alter the equilibrium of the complex colloidal system. It may also require dilution of the dispersion with water which can lead to removal of surface active agent from nanoparticle surface. On this account technique like nuclear magnetic resonance (NMR) and electron spin resonance (ESR) are extremely useful tools for the simultaneous detection of colloidal structures and no sample preparation. These non-destructive methods are fruitful for examining dynamic phenomena and the presence of the nano oil compartments in colloidal lipid dispersions.70

**Magnetic resonance investigation**

NMR spectroscopy (1HNMR) and ESR are employed to enquire about structure of lipid nanoparticles and loaded drug.71 The spectroscopy is used to judge mobility and interaction of oil molecules with solid lipid. This non-invasive technique permits a simple and rapid detection by virtue of width of signal. Proton relaxation times are associated with NMR line width. Mobile oil molecules will give small line widths with high amplitudes, whereas molecules with confined mobility give weak amplitudes and broad signals. Therefore, the technique is apt to evaluate the extent of immobilization.46,71

**Negative staining**

Negative staining is used to increase the electron opacity of the surrounding field. This technique uses salts of various heavy metals to determine the co-presence of colloidal lipid particles in dispersion by TEM. The test sample placed on a metal mesh grid is stained with solutions of heavy metal salts such as uranyl acetate, ammonium molybdate, sodium silicotungstate or sodium phosphotungstate that enhances the contrast. Sections are completely dried before attempting microscopic imaging. Presence of quick dried and stained artefacts makes it tedious to differentiate them from actual colloidal particles. The optical micrographs generated are of low resolution due to grain size stain. Negative staining electron microscopy may give three dimensional projections but problem may arise due to insufficient views on account of attachment of sample to the continuous carbon support in a preferred orientation.46,72

**Electron spin resonance (ESR)**

ESR investigation requires paramagnetic spin probes and no sample preparation. The spectra furnish information about molecular mobility and polarity inside the drug delivery system. This technique gives direct and noninvasive evaluation of the distribution of the spin probe between the aqueous and the lipid phases.46 ESR spectra gives signal for paramagnetic lipids. This tool helps to understand the characteristic properties of nano compartments in lipid carriers.71

**Raman spectroscopy**

It is an excellent tool to answer many questions about structural properties of lipids. The technique requires no preliminary steps and permit detections in the presence of water.63 Fourier-transform infrared spectroscopy and Raman studies are conducted to detect drug-lipid interaction. Raman spectroscopy study excited molecular vibrations produced by a laser beam. The technique is used to map chemical and structural changes in molecules from their transition between two vibrational states. Raman spectroscopy is a useful tool to study packing, conformation and any changes in lipid chain arrangement after loading oils.70

**Structure of skin barrier**

Skin, the largest multilayered organ of the body, with a surface area of 1.7–2.0 m², is composed of several layers: stratum corneum (SC), the viable epidermis, the dermis and lower layers of adipose tissue. The SC, the superficial layer is the main roadblock of the skin. The SC comprises of corneocytes encompassed by lipid domains like long chain ceramides, free fatty acids, cholesterol, sterols and phospholipids.41 Corneocytes are covered by a cornified cell envelope (insoluble) which acts as a critical skin barrier formed by covalent cross-linking of component proteins such as involucrin, loricrin, and the small proline-rich protein.73 The corneocytes are inserted in lipid lamellar locales, which are orientated parallel to the corneocyte surface. Since most drugs administered via skin dependably need to permeate along the tortuous pathway in these lipid locales, the organization and composition of the lipid component is viewed as imperative for the skin hindrance.74,75 It is therefore, the lipids play an essential job in the skin hindrance, which makes their shared course of action in the lamellar areas, a key procedure in the development of the skin obstruction. Low pH of skin, presence of enzymes, skin hydration, diseased state and the transcutaneous concentration gradient are the other factors conceptualizing the barrier property of skin. Percutaneous absorption of topically applied agents also influenced by molecular weight, partition coefficient, formulation design, presence of penetration enhancer.76

**Beneficial role of NLC in transdermal drug delivery**

Transdermal drug delivery system is an established system since ages to attain diverse therapeutic objectives on different structural levels of skin (e.g. surface, epidermis, dermis and hypodermis). However, several problems associated with the conventional topical preparations have come in picture e.g. impermeability to skin barrier, limited efficacy and high frequency of application. The current focus of the researcher is quite related towards exploiting NLC for topical and dermal application,
both in pharmaceutical as well as cosmetic sector. NLCs are composed of biologically active and biodegradable lipids that show less toxicity and offer many favorable attributes such as adhesiveness, occlusion, skin hydration, lubrication, smoothness, emolliency, skin penetration enhancement, modified release, improvement of formulation appearance providing a whitening effect and offering protection of actives against degradation. The key advantageous features offered by NLC that makes its role superior in transdermal drug delivery are as follows:

**Skin permeation**
Umpteen scientific literatures has stated about capability of NLC to control the rate of drug penetration into the skin, which limits the unwanted active absorption into blood circulation. The smaller size of NLCs ensures a nearby contact with SC and can enhance the skin penetration of active compound. Investigators have reached consensus on the routes of nanoparticle penetration (Figure 2) through the skin. Proposed mechanisms for enriched permeation of the particles via the stratum corneum pursued by diffusion of drug are as follows:

1. Unblemished medication loaded vesicle entrance into the diverse layers of the skin.
2. Lipid vesicles acting as penetration enhancers via their skin lipid-fluidizing and modifying property.
3. Induction of nanostructure lipid carrier and skin drug exchange after mingling of carrier lipids with cellular skin lipids.
4. Appendageal route including the hair follicles (HF), pilosebaceous, and sweat gland pores.

Attributable to the hair follicle speaks to an invagination of the epidermis expanding profound into the dermis, which results in a more noteworthy genuine region for drug absorption. The hair follicle has turned into the most essential penetration pathway for nanoparticles among the appendageal routes. Besides, the hair follicles speak to an effective store for topically administered nanoparticles, which are normally extended deep into the tissue up to 2000 μm. Both permeation enhancement and sustained release are attainable by virtue of larger storage volume of hair follicle casts. Drug particle accumulate into the follicular casts followed by diffusion of drug from the nanocarriers into the skin.

Skin penetration of NLCs depends on their composition, and their physicochemical properties like size, aggregation, charge on particle surface, hydrophobicity, solubility of particles in the skin, solubilizing properties of particles towards the skin lipids, and whether particle possess film forming ability.

**Transepidermal water loss (TEWL)**
TEWL is the amount of water that passively evaporates through skin to the external environment due to water vapor pressure gradient on both sides of the skin barrier and is used to characterize skin barrier function. TEWL loss measurements indicate damaged and weakened barrier function of the stratum corneum. An increase in TEWL marks a disruption of the stratum corneum and depletion of intercellular lipids. Topical application of NLC depletes TEWL due to enhanced skin occlusion leading to skin hydration. It was observed that application of NLCs assisted to reduce moisture loss from the skin in comparison to the untreated skin. This owes to the ultrafine size of lipid nanocarriers actinguate high surface area, and improved adhesive properties. The lipid particles forms a uniform compact film over the skin, hence inhibiting water evaporation from the skin. Smaller the size of the particles, the reduced water evaporation from the skin. It was found that the presence of a highly crystalline lipid in formulation decreases moisture loss from the stratum corneum effectively. The presence of emollients (lecithin, propylene glycol) in NLC formulation helps to substitute for the depleted natural lipids present in the space between corneocytes in the stratum corneum to prevent excessive TEWL.

**Skin occlusion**
In general, lipid nanocarriers have peculiar epidermal occlusive characteristics which by inhibiting water evaporation could enhance bioactive penetration into the stratum corneum. Nanoparticles were found to be 15 times more occlusive than microparticles. Müller et al mentioned NLC as “invisible, penetration enhancing occlusive plastic foil.” Scope of NLC occlusive feature depends on the following factors:

- **Particle size:** Small particle size of the nanocarriers diminishes water evaporation from the skin. Occlusion factor of lipid micro particles of >1 μm diameter was found to be 10%, whereas lipid nanoparticles of 200 nm size showed 50% occlusion. Wissing et al also depicts that formation of a monolayer film on skin require 4 mg of topical product with 4% lipid nanoparticles of approx size 200 nm. This occlusive film as shown in Figure 3, being hydrophobic prevents dehydration of the skin,
Owing to less particle size, it has been observed that skin and other whitening effects, lubrication/emolliency and control release properties.37

- Crystallinity and concentration of lipids: High concentration of lipid (50%-60%) present in NLC formulation act as occlusive agent and is responsible for retaining the moisture in the stratum corneum.41 It was found that high occlusivity can be attained with low melting lipids and highly crystalline particles. Formulation having particles size less than 400 nm and at least 35% lipid of high crystallinity was found to be most effective. An increase in oil content in NLC formula causes a decrement in occlusive factor.41 Supercooled melts (noncrystalline nanoparticles) have no occlusive properties.51 An enhanced skin hydration effect showed up due to the occlusive nature of NLCs.84

Skin hydration and elasticity

Usually the human skin sustains a water content of 10%–20% of tissue dry weight. The surface lipid content and moisture state play an important role in the frictional properties of the skin.41 Adequate hydration of skin slows down the signs of aging and protects from environmental damage. NLC fabricated from biocompatible and physiological lipids hold fast to the skin and produce an occlusive action expanding skin hydration. Lipid nanoparticles also retard moisture loss, hence loosen the corneocyte packing. The expanded intercorneocyte gap in turn leads to enhanced drug penetration.85 NLCs could extend this superior hydration attribute due to its ultrafine size. Ascribed to small size lipid nanoparticles cling to lipid film of stratum corneum (hydrophobic interactions). The adsorbed film reconditions damaged skin and thus restores a protective thin film.86 Owing to less particle size, the dimensions of the capillary channels of nanometer pores will be much smaller; thus, the hydrodynamic evaporation of water will decrease.53,87

Loo et al depicted a high concentration of lipids in NLCs increase hydration more effectively as a consequence of occlusive layer. It is because of sliding of additional lipids into the intercellular space of the skin that assist in less TEWL.82 Presence of humectants in formulation has an additional effect on hydration of SC by attracting moisture from dermis and air. Tichota et al formulated argan oil NLC-based hydrogel manifesting a synergistic effect on skin hydration (NLC occlusion plus argan oil hydration).48

Skin hydration can be measured using a corneometer. The instrument works on the mechanism of measuring capacitance or conductance of a dielectric medium. As the hydration level of stratum corneum increases, its dielectric property alters. The method is simple, quick and hardly affected by skin residues.82 It has been observed that skin hydration gets amplified with increased concentration of lipids.41 Skin microrelief is used to evaluate skin-hydration efficacy of cosmetics, and could be assessed by measuring the parameters of roughness, scaling, smoothing, and wrinkling.48 The moisturisation effect of a product leads to the increase in skin hydration, which contributes to wrinkle smoothing and enhancing the penetration of bioactives into specific skin layers.82 Any alteration in the hydration level of the skin are measured in arbitrary units.

Stability of bioactives

One of the most important features of lipid nanoparticles is the ability to retard the chemical degradation of actives by photochemical, hydrolytic and oxidative pathways. Chemical stability of drug molecule stoutly depends on solid lipid matrix of lipid nanoparticles. Researchers remarked that the chemical stability of NLC fabricated with less crystalline solid lipid and lattice imperfection were improved due to increased drug arrangement within the lipid matrix. Solid state minimizes the exchange of actives with water phase (diffusional law by Einstein).89 Moreover, the structure and good chemical stability of lipid itself must be reviewed. Hence, the selection of most suitable lipid during preformulation studies is quite important. It has been noted in research that actives that are incorporated in the imperfections at the less crystalline lipid matrix of NLC provide prolonged physical stability.85 Table 3 displays a brief literature of drugs incorporated in NLC to increase stability.

Prolonged effect

Release profile from lipid nanoparticles is drastically influenced by type of lipid (solid or oil) used to formulate the vehicle, concentration of surfactant (or surfactants), solubility and concentration of active in the lipid matrix and method of formulating NLC.77 NLC are produced by controlled mixing of solid lipids with spatially incompatible liquid lipids leading to special nanostructures with improved drug incorporation and release properties. Table 4 present a review of work done for extending drug release using NLC.

Skin targeting

Targeted drug delivery to the epidermal layer could display immense benefits over systemic administration on countless therapies. For the treatment of skin ailments like acne, a fungus infection or hair fall; the efficacy of topical drug is speculated by their potential to reach the
desired site of action (specific skin layers) and remain there in therapeutic effective concentration for the appropriate time. Poor therapeutic effects & adverse reactions exhibited by conventional topical carriers can be conquered by formulating dermal NLC. 21 The strategy to target epidermis layer is favorable in respect of safety and as well as a rich network of antigen-presenting cells in epidermis eliciting a higher immune response. 78 Researchers are yet to be in unison about the fact that which particle property would result in superior skin targeting. It has been found that drug characteristics like size of particulate carrier, surface charge and composition material affect skin permeation and pharmacodynamics of encapsulated drugs. Degree of drug binding with plasma protein affect the epidermal targeting and penetration of particle deep into HF, on account of the capillary network around this structure, predominantly in the growth phase. Following accumulation in HF, nanoparticles can diffuse rapidly and continuously into the dermis or subcutaneous region enhancing epidermal targeting as well as local delivery of drug. 79

It was observed that adjusting the size of particulate carriers enables an intra- or transfollicular penetration (Figure 4) and drug delivery. Particles of different sizes and structures accumulate in the hair follicle openings and penetrate along the follicular duct, when applied onto the skin. Particle-based drug delivery systems can be used to target specific regions within the follicular duct as penetration depths are counted upon the size of the particles and on the hair follicle type. The motion of the hair may likewise add to the penetration of nanoparticles of a size of 20 nm. 77 Lipids that resemble the composition of sebum may likewise advance follicular penetration as a high sebum/water partition coefficient is a basic characteristic for transport into HF. Epidermal targeting may also be assumed due to a dissolution or erosion of
nanostructure lipid carriers

Table 4. Literature review of drugs incorporated into NLC for prolonged release

| Name of the drug | Method of Preparation | Objective of Prolonged release | Details | Ref. |
|------------------|-----------------------|-------------------------------|---------|-----|
| Aceclofenac       | Melt-emulsification and low-temperature solidification method or ultrasonication method or high-speed homogenizer method | To formulate a controlled-release drug delivery system for a prolonged period to satisfy the goals of the treatment of arthritis like reducing pain and inflammation | 1. Oleic acid played an important role in the release of aceclofenac from the NLC dispersion. 2. Liquid lipid being located in the outer shell of the nanoparticles, leading to a drug-enriched shell that is related to burst release at the initial stage. 3. No significant effect of the method of preparation on the release of drug. | 42 |
| Amoitone B        | Emulsion-evaporation and low-temperature-solidification technology | To construct an effective delivery system for Amoitone B to realize sustained release, thus prolong drug circulation time in body and improve the bioavailability. | 1. When contacting the release solution, the superficial drug was freed quickly, leading to the burst release in the initial stage. 2. With the degradation and erosion of lipid matrix, the drug incorporated into nanoparticles core was released in a prolonged way. | 95 |
| Oridonin          | Emulsion-evaporation and low-temperature-solidification technique | To prepare oridonin-loaded NLC in which the Nanoparticles can be obtained in mild conditions easily without the need of any special equipment and the sustained drug release can also be achieved. | 1. During emulsification, at first, most of the drug was dispersed in lipid droplets due to low solubility in water. 2. With increasing temperature and the existence of surfactant which increased drug solubility in the water, drug was migrated from the lipid phase to water phase. 3. During the cooling of the produced O/W nanoemulsion, a re-partitioning of the drug into the lipid phase occurred. 4. When reaching the recrystallization temperature of the lipid, the solid lipid core was rapidly solidified to form a solid lipid core in which liquid lipid was randomly distributed. | 96 |

lipid particles in sebum. Manipulating surface charge can also be used as an approach for targeting.78

Drug molecules incorporated into NLC for skin targeting
Podophyllotoxin, oxiconazole nitrate, clobetasol, curcumin, tretinoin, minoxidil, finasteride, diphenycyprone, terbinafine hydrochloride.

Regulatory perspective
One of the significant grounds for the wide acceptance and commercial success of NLC is that these carriers present minor regulatory obstacles. The nanostructure lipid carriers employ lipids and emulsifiers with physiological, nontoxic, biodegradable and compatible profiles. All the ingredients used are acknowledged GRAS status by regulatory authorities or already have been accepted for encapsulating pharmaceutical or food active compounds. Still in any case, it is essential to use all the ingredients in safe and accepted range. Most of them are obtained or consist of ingredients occurring naturally in the human body i.e. fatty acid & glycerol. These are known to be well tolerated and reduce cytotoxic or adverse drug reaction.22,77,83

Patent status of NLC
Over the past decade, nanostructure lipid carriers have been exploited for formulating a number of transdermal and cosmetic agents. Various patents have been granted for nano-lipid formulations. Table 5 presents a brief review of patents on the subject of original invention in the nanostructure lipid carriers.

Conclusion and Future Perspective
NLC provide a large influence to the enormous bars that are a prerequisite in formulating a stable drug delivery system. The application of nanocarriers in transdermal drug delivery has proclaimed a new domain in the drug delivery. NLCs are chemically and physically stable system with improved drug incorporation and increased bioavailability. The increasing interest of industry in lipid carrier system has been remarkably expanding the advancements in latest years. At present more than 30 commercial NLC formulations are accessible in the market containing drug and cosmetics ingredient. NLC as smarter generation of lipid nanoparticles are promising candidates to provide skin targeting along with occlusive effect and prolonged release. Lipid nanocarriers are seeking industrial attention due to qualified and validated scale up of technology, GRAS status of excipients and easy large scale production. Future NLC formulations can bring more prosperity to the lipid carrier system because of its umpteen superior characteristics over first generation systems. Future concern also involves assessment of toxicity and health hazard associated with nanostructures. More research in preclinical and clinical investigation will pave the way to success for nano-lipid structures. Achievement in this field can be conceived if
Table 5. Patent status of NLC

| Patent Name                                                                 | Patent Number    | Inventors   | Publication Date | Reference |
|-----------------------------------------------------------------------------|------------------|-------------|------------------|-----------|
| Novel nano-lipid carrier for injection embodying paclitaxel series substances and preparation method thereof | CN101366697A     | Liu et al   | 18/2/2009        | 98        |
| Nanostructured lipid carriers containing riluzole and pharmaceutical formulations containing said particles | EP20070764871    | Bondi et al | 20/10/2010       | 99        |
| Use of nano structured lipid carrier drug feeding system                     | CN101129335A     | Jian et al  | 22/9/2010        | 100       |
| Composite anti-screening agent nanostructured lipid carrier and preparation method thereof | CN102688152A     | Qiang et al | 26/9/2012        | 101       |
| Lipid nanoparticle capsules                                                  | US 2013/0017239 A1 | Petit et al | 17/1/2013        | 102       |
| Bionic lovastatin nano-structured lipid carrier and preparation method thereof | CN102915077A     | Jianping et al | 20/2/2013      | 103       |
| Coenzyme Q nanostructured lipid carrier and preparation method thereof       | CN101658468A     | Summer et al | 6/3/2013        | 104       |
| Nanoparticle formulations for skin delivery                                  | US8715736B2      | Sachdeva et al | 06/05/2014  | 105       |
| A composition for treating leukemia                                           | WO2014123406A1   | Abdullah et al | 14/8/2014   | 106       |
| A method for producing nano lipid formulation for skin care and/or repair and a nano lipid formulation of the same | WO2015105407A1   | Ujang et al | 16/7/2015       | 107       |
| Lipid nanoparticles for wound healing                                        | EP2821077A1      | Lafuente et al | 7/01/2015   | 108       |
| Preparation of nanostructured lipid carriers (NLC) method and products made | CN102283809B     | Ismail et al | 14/12/2016      | 109       |
| Nano-structured lipid carrier comprising α-tocopherol and preparing method thereof | KR101777616B1 | Geun et al | 13/9/2017       | 110       |
| Nanopreparation of guided and targeted on-demand substance delivery          | US Patent Application 20170119891 | Lal et al | 4/5/2017        | 111       |

pharmaceutical industry picks up the academia research to style this carrier system for various therapeutic and cosmetic agents.

**Ethical Issues**
Not applicable.

**Conflict of Interest**
The author declares that this article content has no conflict of interest.

**References**

1. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. *Indian J Pharm Sci* 2009;71(4):349-58. doi: 10.4103/0250-474x.57282
2. López-García R, Ganem-Rondero A. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC): Occlusive Effect and Penetration Enhancement Ability. *J Cosmet Dermatol Sci Appl* 2015;5(2):62-72. doi: 10.4236/jcdsa.2015.52008
3. Poonia N, Kharb R, Lather V, Pandita D. Nanostructured lipid carriers: versatile oral delivery vehicle. *Future Sci OA* 2016;2(3):FSO135. doi: 10.4155/fsoa-2016-0030
4. Jain P, Rahi P, Pandey V, Asati S, Soni V. Nanostructure lipid carriers: a modish contrivance to overcome the ultraviolet effects. *Egypt J Basic Appl Sci* 2017;4(2):89-100. doi: 10.1016/j.ejbas.2017.02.001
5. Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. *Artif Cells Nanomed Biotechnol* 2016;44(1):27-40. doi: 10.3109/21691401.2014.909822
6. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. *Adv Pharm Bull* 2015;5(3):305-13. doi: 10.15171/apb.2015.043
7. Kaur S, Nautyal U, Singh R, Singh S, Devi A. Nanostructure lipid carrier (NLC): the new generation of lipid nanoparticles. *Asian Pac J Health Sci* 2015;2(2):76-93. doi: 10.21276/aphs.2015.2.2.14
8. Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. *Lipids Health Dis* 2012;11:159. doi: 10.1186/1476-511x-11-159
9. Iglic A, Kulkarni C, Rappolt M. Advances in Biomembranes and Lipid Self-Assembly. 1st ed. UK: Academic Press; 2016.
10. Shah R, Eldridge D, Palombo E, Harding I. Lipid Nanoparticles: Production, Characterization and Stability. UK: Springer; 2015.
11. Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. *Recent Pat Nanotechnol* 2013;7(1):41-55. doi: 10.2174/1872210511307010041
12. Noor NM, Sheikh K, Somavarapu S, Taylor KMG. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery. *Eur J Pharm Biopharm* 2017;117:372-84. doi: 10.1016/j.ejpb.2017.04.012
13. Imran M, Shah MR, Ullah S. Lipid-Based Nanocarriers for Drug Delivery and Diagnosis. UK: Elsevier; 2017.
14. Karn-Orachai K, Smith SM, Phumpree S, Treethong A, Puttipipatkhachorn S, Pratontep S, et al. The effect of surfactant composition on the chemical and structural properties of nanostructured lipid carriers. *J Microencapsul* 2014;31(6):609-18. doi: 10.3109/02652048.2014.913374
15. Han F, Li S, Yin R, Liu H, Xu L. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: nanostructured lipid carriers.
Colloids Surf A Physicochem Eng Asp 2008;315(1-3):210-6. doi: 10.1016/j.colsurfa.2007.08.005

16. Nithihan K, Leelapornpisid P, Natakankitkul S, Chaiyana W, Mueller M, Viernstein H, et al. Improvement of stability and transdermal delivery of bioactive compounds in green robusta coffee beans extract loaded Nanostructured lipid carriers. J Nanotechnol 2018;2018:7865024. doi: 10.1155/2018/7865024

17. Keck CM, Baisaeng N, Durand P, Prost M, Meinke MC, Muller RH. Oil-enriched, ultra-small nanostructured lipid carriers (usNLC): a novel delivery system based on flip-flop structure. Int J Pharm 2014;477(1-2):227-35. doi: 10.1016/j.ijpharm.2014.10.029

18. Affandi MMM, Julianto T, Majeed A. Development and stability evaluation of astaxanthin nanoemulsion. Asian J Pharm Clin Res 2011;4:Suppl 1:142-8.

19. Arora R, Katiyar SS, Kushwah V, Jain S. Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: a comparative study. Expert Opin Drug Deliv 2017;14(2):165-77. doi: 10.1080/17425247.2017.1264386

20. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine 2007;2(3):289-300.

21. Leonida MD, Kumar I. Bionanomaterials for Skin Regeneration. Switzerland: Springer International Publishing; 2016. p. 55-6.

22. Grumezescu AM, Nanobiomaterials in Galenic Formulations and Cosmetics: Applications of Nanobiomaterials. Vol 10. 1st ed. Kidlington, UK: William Andrew; 2016.

23. Hernández-Sánchez H, Gutiérrez-López GF. Food Nanoscience and Nanotechnology. New York: Springer; 2015. p. 124-5.

24. Wong HL, Li Y, Rendayan R, Rauth MA, Wu XY. Solid lipid nanoparticles for anti-tumor drug delivery. In: Amiji MM, ed. Nanotechnology for Cancer Therapy. Boca Raton: CRC press, Taylor & Francis Group; 2007.

25. Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target 2012;20(10):813-30. doi: 10.3109/1061186X.2012.716845

26. Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution. U.S. Patent No. 5250236, 1993.

27. Qidwai A, Khan S, Md S, Fazil M, Baboota S, Narang JK, et al. Nanostructured lipid carrier in photodynamic therapy for the treatment of basal-cell carcinoma. Drug Deliv 2016;23(4):1476-85. doi: 10.3109/1061186X.2016.1165310

28. Joshi MD, Prabhu RH, Patravale VB. Fabrication of Nanostructured Lipid Carriers (NLC)-Based Gels from Microemulsion Template for Delivery Through Skin. Methods Mol Biol 2019;2000:279-92. doi: 10.1007/978-1-4939-9516-5_19

29. Shi L, Li Z, Yu L, Jia H, Zheng L. Effects of surfactants and lipids on the preparation of solid lipid nanoparticles using double emulsion method. J Dispers Sci Technol 2011;32(2):254-9. doi: 10.1080/01932691003659130

30. Uner M. Preparation, characterization and physicochemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as coloidal drug carrier systems. Pharmazie 2006;61(5):375-86.

31. Schubert MA, Müller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles—evaluation of the method and process parameters. Eur J Pharm Biopharm 2003;55(1):125-31. doi: 10.1016/s0939-6411(02)00130-3

32. Anuradha K, Senthil Kumar M. Development of Lacidipine loaded nanostructured lipid carriers (NLCs) for bioavailability enhancement. Int J Pharm Med Res 2014;2(2):50-7.

33. Üner M, Karaman EF, Aydoğmuş Z. Solid lipid nanoparticles and nanostructured lipid carriers of loratadine for topical application: physicochemical stability and drug penetration through rat skin. Trop J Pharm Res 2014;13(5):653-60. doi: 10.4314/tjpr.v13i5.1

34. Pinheiro M, Ribeiro R, Vieira A, Andrade F, Reis S. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug Des Devel Ther 2016;10:2467-75. doi: 10.2147/dddt.s104395

35. Keservani RK, Sharma AK, Kesharwani RK. Nanocarriers for Brain Targeting: Principles and Applications. 1st ed. Toronto: Apple Academic Press; 2019.

36. Probe-Type Sonication vs. Ultrasound Bath: An Efficiency Comparison. Available from: https://www.hielscher.com/probe-type-sonication-vs-ultrasound-bath-an-efficiency-comparison.htm. Accessed Feb 23, 2019.

37. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56(9):1257-72. doi: 10.1016/j.addr.2003.12.002

38. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion-based process for the preparation of lipid Nanocarriers. Pharm Res 2002;19(6):875-80. doi: 10.1023/a:1016121319668

39. Bodmeier R, Huagang C. Indomethacin polymeric nanosuspensions prepared by microfluidization. J Control Release 1990;12(3):223-33. doi: 10.1016/0168-3659(90)90103-Z

40. Charcosset C, El-Harati A, Fessi H. Preparation of solid lipid nanoparticles using a membrane contactor. J Control Release 2005;108(1):112-20. doi: 10.1016/j.jconrel.2005.07.023

41. Loo C, Basri M, Ismail R, Lau H, Tejo B, Kanthimathi M, et al. Effect of compositions in nanostructured lipid carriers (NLC) on skin hydration and occlusion. Int J Nanomedicine 2013;8:13-22. doi: 10.2147/ijn.s35648

42. Patel D, Dasgupta S, Dey S, Ramani YR, Ray S, Mazumder B. Nanostructured lipid carriers (NLC)-based gel for the topical delivery of aceclofenac: preparation, characterization, and in vivo evaluation. Sci Pharm 2012;80(3):749-64. doi: 10.3797/scipharm.1202-12

43. Uprit S, Kumar Sahai R, Roy A, Pare A. Preparation and characterization of minoxidil loaded SLNs and NLCs? A comparative study. Eur J Pharm Sci 2014;56(9):90103-Z

44. D90, D50, D10, and span – for DSL? https://www.materials-talks.com/blog/2016/08/25/d90-d50-d10-and-span-for-dls/. Accessed on 23 Aug 2019

45. Das S, Ng WK, Tan RB. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs)? development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci 2012;47(1):139-51. doi: 10.1016/j.ejps.2012.05.010

46. Nastruzzi C. Lipospheres in Drug Targets and Delivery: Approaches, Methods, and Applications. Florida: CRC Press; 2004. p. 15.
47. Babick F. Suspensions of Colloidal Particles and Aggregates. Switzerland: Springer International Publishing; 2016.
48. Rajnikanth PS, Chellian J. Development and evaluation of nanostructured lipid carrier-based hydrogel for topical delivery of 5-fluorouracil. Int J Nanomedicine 2016;11:5067-77. doi: 10.2147/ijn.s17511
49. Esposito E, de Vries HE, van der Pol SMA, Boschi F, Calderan L, Mannucci S, et al. Production, physicochemical characterization and biodistribution studies of lipid nanoparticles. J Nanomol Nanotechnol 2015;6(1):256. doi: 10.4172/2157-7439.1000256
50. Lu GW, Gao P. Emulsions and Microemulsions for Topical and Transdermal Drug Delivery. In: Kulkarni VS, ed. Handbook of Non-Invasive Drug Delivery Systems. 1st ed. UK: William Andrew; 2010.
51. Thatipamula R, Palem C, Gannu R, Mudragada S, Yamsani M. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. Daru 2011;19(1):23-32.
52. Harisa GI, Alomrani AH, Badran MM. Simvastatin-loaded nanostructured lipid carriers attenuate the atherogenic risk of erythrocytes in hyperlipidemic rats. Eur J Pharm Sci 2017;96:62-71. doi: 10.1016/j.ejps.2016.09.004
53. Biopharmaceutical research and development service, Contract analytical services, Zeta potential. Available from: https://www.coriolis-pharma.com/contract-analytical-services/zeta-potential/. Accessed February 17, 2019.
54. Kuntsche J, Horst JC, Bunjes H. Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems. Int J Pharm 2011;417(1-2):120-37. doi: 10.1016/j.ijpharm.2011.02.001
55. Stewart PL. Cyro-electron microscopy and cryo-electron tomography of nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2017;9(2):e1417. doi: 10.1002/wnan.1417
56. Grumezescu AH. Emulsions. Nanotechnology in the Agri-Food Industry. 1st ed. UK: Academic Press; 2016.
57. Wang J, Wang H, Zhou X, Tang Z, Liu G, Liu G, et al. Physicochemical characterization, photo-stability and cytotoxicity of coenzyme Q10 loading nanostructured lipid carrier. J Nanosci Nanotechnol 2012;12(3):2136-48. doi: 10.11606/jn.2012.5790
58. Doktorovova S, Souto EB. Nanostructured lipid carrier-based hydrogel formulations for drug delivery: a comprehensive review. Expert Opin Drug Deliv 2009;6(2):165-76. doi: 10.1517/17425240802712590
59. Gaba B, Fazil M, Khan S, Ali A, Baboota S, Ali J. Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride. Bull Fac Pharm Cairo Univ 2015;53(2):147-59. doi: 10.1016/j.bfpccu.2015.10.001
60. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011;12(1):62-76. doi: 10.1208/s12249-010-9563-0
61. Beck R, Guterner S, Pohlmann A. Nanocosmetics and Nanomedicines: New Approaches for Skin Care. Berlin: Springer; 2014.
62. Gönülül Ü, Üner M, Yener G, Karaman EE, Aydınmuş Z. Formulation and characterization of solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsion of lornoxicam for transdermal delivery. Acta Pharm 2015;65(1):1-13. doi: 10.1515/acph-2015-0009
63. Shah R, Eldridge D, Palombo E, Harding I. Lipid Nanoparticles: Production, Characterization and Stability. London: Springer; 2015.
64. Zhou L, Chen Y, Zhang Z, He J, Du M, Wu Q. Preparation of tripterygen nanostructured lipid carriers and their absorption in rat intestine. Pharmazie 2012;67(4):304-10.
65. Teeranachaideekul V, Muller RH, Junyparsert VB. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)—effects of formulation parameters on physicochemical stability. Int J Pharm 2007;340(1-2):198-206. doi: 10.1016/j.ijpharm.2007.03.022
66. Hommos A. Nanostructured lipid carriers (NLC) in dermal and personal care formulations [dissertation]. Berlin: Freie Universität Berlin; 2008.
67. Grumezescu AM. Design of Nanostuctures for Versatile Therapeutic Applications. UK: William Andrew; 2017.
68. Roohinejad S, Greiner R, Oey I, Wen J. Emulsion-based Systems for Delivery of Food Active Compounds: Formation, Application, Health and Safety. USA: John Wiley & Sons Ltd; 2018.
69. Schäfer-Korting M. Drug Delivery, Handbook of Experimental Pharmacology. Berlin: Springer; 2010.
70. Ahmad MU. Lipids in Nanotechnology. 1st ed. Urban: AOCQS Press; 2012.
71. Jores K, Mehnert W, Mäder K. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: a nuclear magnetic resonance and electron spin resonance study. Pharm Res 2003;20(8):1274-83. doi: 10.1023/A:102506518309
72. Thompson RE, Walker M, Siebert CA, Muench SP, Ranson NA. An introduction to sample preparation and imaging by cryo-electron microscopy for structural biology. Methods 2016;100:3-15. doi: 10.1016/j.ymeth.2016.02.017
73. Gilaberte Y, Prieto-Torres L, Pastorshenko I, Juarranz A. Anatomy and Function of the Skin. In: Hamblin MR, Avci P, Prow TW, eds. Nanoscience in Dermatology. UK: Academic Press; 2016. p. 1-14. doi: 10.1016/B978-0-12-802926-8.00001-X
74. Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, Ponec M. Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res 2003;42(1):1-36. doi: 10.1016/s0163-7827(02)00028-0
75. Hua S. Lipid-based nano-delivery systems for skin delivery of drugs and bioactives. Front Pharmacol 2015;6:219. doi: 10.3389/fphar.2015.00219
76. El Maghraby GM, Barry BW, Williams AC. Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci 2008;34(4-5):203-22. doi: 10.1016/j.ejps.2008.05.002
77. Puglia C, Bonina F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin Drug Deliv 2012(9):429-41. doi: 10.1517/17425247.2012.669687
78. Rancan F, Vogt A. Getting under the skin: what is the potential of the transfollicular route in drug delivery? Ther Deliv 2014;5(5):875-7. doi: 10.4155/tde.14.56
79. Honari G, Maibach HI. Skin Structure and Function. In: Maibach H, Honari G, eds. Applied Dermatotoxicology. 1st ed. Academic Press; 2010. p. 1-10. doi: 10.1016/B978-0-12-420130-9.00001-3
80. Müller RH, Petersen RD, Hommos A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007;59(6):522-30. doi: 10.1016/j.addr.2007.04.012
81. Wissing S, Muller R. The influence of the crystallinity of
lipid nanoparticles on their occlusive properties. *Int J Pharm* 2002;242(1-2):377-9. doi: 10.1016/s0378-5173(02)00220-x.

82. Loo CH, Ismail R, Basri M, Lau HLN, Tejo BA, Hassan HA, et al. Nanostructured lipid carriers (NLC): present state of development and industrial applications. *Curr Drug Discov Technol* 2011;8(3):207-27. doi: 10.2174/157016311796799062.

83. Müller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN and NLC): progress state of development and industrial applications. *Curr Drug Discov Technol* 2011;8(3):207-27. doi: 10.2174/157016311796799062.

84. Müller RH, Radke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. *Adv Drug Deliv Rev* 2002;54 Suppl 1:S131-55. doi: 10.1016/s0169-409x(02)00118-7.

85. Gelfuso GM, Cunha-Filho MS, Gratieri T. Nanostructured lipid carriers for targeting drug delivery to the epidermal layer. *Ther Deliv* 2016;7(11):735-7. doi: 10.4155/tde-2016-0059.

86. Souto EB, Müller RH. Cosmetic features and applications of lipid nanoparticles (SLN, NLC). *Int J Cosmet Sci* 2008;30(3):157-65. doi: 10.1111/j.1468-2494.2008.00433.x.

87. Gomhommazadeh S, Mokhtari M, Jaafari MR. Preparation, characterization, and evaluation of moisturizing and UV protecting effects of topical solid lipid nanoparticles. *Braz J Pharm Sci* 2012;48(4):683-90. doi: 10.1590/S1984-82502012000012.

88. Tichota DM, Silva AC, Sousa Lobo JM, Amaral MH. Design, characterization, and clinical evaluation of argan oil nanostructured lipid carriers to improve skin hydration. *Int J Nanomedicine* 2014;9:3855-64. doi: 10.2147/ijn.s46008.

89. Müller RH. Lipid Nanoparticles for Improved Formulation of Cosmetic and Pharmaceutical Actives. Free University Technology Presentation; 2007.

90. Li B, Ge ZQ. Nanostructured lipid carriers improve skin permeation and chemical stability of idebenone. *AAPS PharmSciTech* 2012;13(1):276-83. doi: 10.1208/s12249-011-0974-3.

91. Wang J, Tang J, Zhou X, Xia Q. Physicochemical characterization, identification and improved photostability of alpha-lipoic acid-loaded nanostructured lipid carrier. *Drug Dev Ind Pharm* 2014;40(2):201-10. doi: 10.3109/03639045.2012.753901.

92. Pamudji JS, Mauludin R, Indriani N. Development of nanostructured lipid carrier formulation containing of retinyl palmitate. *Int J Pharm Sci* 2016;8(2):256-60.

93. Mitri K, Shegokar R, Gohla S, Anselmi C, Muller RH. Lipid nanoparticles for dermal delivery of lutein: preparation, characterization, stability and performance. *Int J Pharm* 2011;414(1-2):267-75. doi: 10.1016/j.ijpharm.2010.05.008.

94. Fan H, Liu G, Huang Y, Li Y, Xia Q. Development of a nanostructured lipid carrier formulation for increasing photo-stability and water solubility of Phenylethyl Resorcinol. *Appl Surf Sci* 2014;288:193-200. doi: 10.1016/j.apsusc.2013.10.006.

95. Luan J, Zhang D, Hao L, Li C, Qi L, Guo H, et al. Design and characterization of Amortoin Bio-loaded nanostructured lipid carriers for controlled drug release. *Drug Deliv* 2013;20(8):324-30. doi: 10.3109/10717554.2013.835007.

96. Jia L, Shen J, Zhang D, Duan C, Liu G, Zheng D, et al. In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. *Int J Biol Macromol* 2012;50(3):523-9. doi: 10.1016/j.ijbiomac.2012.01.024.

97. Zhao J, Piao X, Shi X, Si A, Zhang Y, Feng N. Podophyllotoxin-loaded nanostructured lipid carriers for skin targeting: in vitro and in vivo studies. *Molecules* 2016;21(11). doi: 10.3390/molecules21111549.

98. Liu D, Ning R, Song J, Li L, Minghui L, Shubin L, et al. inventors; Shenyang Wanai Pride Medical Technology Co., Ltd. Assignee. Nanostructured lipids carriers containing rhizole and pharmaceutical formulations containing said particles. European Patent Office. EP20070764871, 2009 Oct 20.

99. Bondi ML, Giammona G, Craparo EF, Drago F. inventors; Consiglio Nazionale Delle Richerche., assignee. Nanosructured lipids carriers containing rhizole and pharmaceutical formulations containing said particles. European Patent Office. EP20070764871, 2009 Oct 20.

100. Jia L, Shen J, Zhang D, Duan C, Liu G, Zheng D, et al. inventors; Shenyang Wanai Pride Medical Technology Co., Ltd. Assignee. Nanostructured lipids carriers containing rhizole and pharmaceutical formulations containing said particles. European Patent Office. EP20070764871, 2009 Oct 20.